Cystic Fibrosis Foundation
6931 Arlington Road
57 articles with Cystic Fibrosis Foundation
Cystic Fibrosis Foundation Launches Inaugural Golden Ticket Competition to Find the Next Genetic Therapies for CF
Cystic Fibrosis Foundation Launches Inaugural Golden Ticket Competition to Find the Next Genetic Therapies for CF.
Bakar Labs and the Cystic Fibrosis Foundation Support Entrepreneurs to Develop New Genetic Therapies for CF
Bakar Labs, the incubator at UC Berkeley's Bakar BioEnginuity Hub (BBH), announced today a unique collaboration with the Cystic Fibrosis Foundation to accelerate the application of new technologies for the treatment of cystic fibrosis.
Today, the Cystic Fibrosis Foundation announced an award to Eloxx Pharmaceuticals Inc. for up to $15.9 million in additional funding to support the expansion of its ongoing ELX-02 clinical program focused on developing therapies for people with CF who have nonsense mutations.
Eloxx Pharmaceuticals, Inc. today announced that the Company has received additional funding of a Therapeutic Development Award of up to $15.9 million from the CF Foundation to support the ongoing ELX-02 clinical program.
Cystic Fibrosis Foundation Invests in Felix Biotechnology as They Advance New Therapies Targeting Chronic Infections in Cystic Fibrosis
Felix Biotechnology today announced it received a strategic investment from the Cystic Fibrosis Foundation as part of a Therapeutics Development Award.
Dr. Steven Rowe will support mission to cure cystic fibrosis by leading the Foundation’s research strategy, focusing on genetic therapies.
Cystic Fibrosis Foundation Announces Investment in SalioGen Therapeutics to Fund Genetic Therapies Research
The Cystic Fibrosis Foundation announced today that it has invested in SalioGen Therapeutics to support the company’s preclinical research into a novel genetic therapy for cystic fibrosis.
Peptilogics Receives Award from the Cystic Fibrosis Foundation to Investigate PLG0301 and PLG0206 as Potential Dual-Acting Treatments for Lung Infections Associated with Cystic Fibrosis
Peptilogics today announced that the company received an award from the Cystic Fibrosis Foundation.
Study reaffirms the Foundation’s commitment to advance solutions to the growing challenge of antibiotic resistance.
Pulmocide Ltd. today announced a $3.5 million investment from the Cystic Fibrosis Foundation for the development of opelconazole for lung transplant recipients.
The Cystic Fibrosis Foundation announced the recipients of its sixth annual Impact Grants, which provide up to $10,000 of funding per year for up to two years to individuals and nonprofit organizations within the cystic fibrosis community who are leading projects to support people living with the disease.
The Cystic Fibrosis Foundation announced the initiation of the HERO-2: Home Reported Outcomes Study, a first-of-its-kind, at-home observational study that aims to characterize the range of outcomes people experience while using Trikafta®.
New funding awards include up to $2.6M to Eloxx Pharmaceuticals to identify potential therapies for CF nonsense mutations
SpliSense, which focuses on cystic fibrosis and other genetic pulmonary diseases, closed on a $28.5 million Series B financing round. The company plans to use the money to advance its pipeline.
Company to use its novel gene editing technology to explore a potential in vivo gene therapy treatment for cystic fibrosis
The Cystic Fibrosis Foundation announced that it has awarded up to $2.17 million to Beyond Air® to support the development of a portable inhaled nitric oxide treatment for nontuberculous mycobacteria, difficult-to-treat bacteria that infect the lungs of people with cystic fibrosis.
the Cystic Fibrosis Registry Global Harmonization Group, including the Cystic Fibrosis Foundation, published findings from the first global study on the impact of COVID-19 on children with cystic fibrosis.
the Cystic Fibrosis Foundation announced it has awarded up to $3.3 million to Polyphor AG to develop an inhaled version of murepavadin, an antibiotic that targets multi-drug resistant Pseudomonas aeruginosa infections in people with cystic fibrosis.
The Cystic Fibrosis Registry Global Harmonization Group, including the CF Foundation, published in the Journal of Cystic Fibrosis updated data on the impact of COVID-19 on people with cystic fibrosis.
Today, the Cystic Fibrosis Foundation announced a new research award of up to $2.4 million to Calithera Biosciences Inc. to advance a potential treatment to reduce infections in the lungs of people with cystic fibrosis. Individuals with CF who have chronic infections are at greater risk for worsening, life-threatening lung disease,